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Summary 
Recent epidemiologic studies suggest that elevated 
homocysteine concentrations in plasma represent a 
risk factor for vascular disease and stroke. In the 
present study, we analyzed plasma samples from the 
20th biannual examination of the Framingham Heart 
Study cohort to determine distribution of plasma 
homocysteine concentrations, with emphasis on 
relationships to vitamins that are involved in 
homocysteine metabolism and prevalence of carotid 
artery stenosis. Results showed that homocysteine 
was positively correlated with age. After controlling 
for age and sex, homocysteine exhibited strong 
inverse correlation with plasma folate, and weaker 
correlations with plasma vitamin Bl2 and pyridoxal-
5' -phosphate. Homocysteine was also inversely cor-
related with intakes of folate and vitamin B6, but not 
vitamin B l2 • Prevalence of high homocysteine 
(>14~mol!L) was 29.3% in this cohort, and 
inadequate plasma concentrations of one or more 
B vitamins appeared to contribute to 67% of the 
cases of high homocysteine. After adjustment for 
sex, age, HDL cholesterol, systolic blood pressute, 
and cigarette smoking, the prevalence of carotid-
artery stenosis ~25% was 43% in men and 34% 
in women with an odds ratio of 2.0 for individuals 
in the highest homocysteine quartile, compared 
with those in the lowest quartile (p < 0.001). 
Plasma concentrations of folate and pyridoxal-
5' -phosphate and folate intake were inversely associ-
ated with extracranial carotid stenosis after adjust-
ment for age, sex, and other risk factors. These data 
indicate that hyperhomocysteinemia is prevalent 
(30%) in this aged population, and that it is associ-
ated with increased risk of extracranial carotid-artery 
stenosis. Insufficient levels of folate, and, to a lesser 
extent, vitamin B6, appear to predict part of this 
elevated risk through their role in homocysteine 
metabolism. 
Introduction 
In recent years, there have been· growing indications 
suggesting that moderate elevations of homocysteine 
in plasma are a risk factor for occlusive vascular dis-
ease and stroke [l-3J. A literature survey by Ueland 
et al. [1 J identified a total of 21 studies involving 
more than 1,500 patients with occlusive (cardiovascu-
lar, peripheral, and cerebrovascular) vascular disease 
and more than 1,500 respective controls. Sixteen of 
these studies reported significantly higher mean 
plasma homocysteine concentrations in patients than 
in respective controls (p < 0.05 to < 0.001). The mean 
patient/control homocysteine ratio according to this 
survey was 1.31, which indicates that the elevation 
of homocysteine in these patients is mild and cer-
tainly not as severe as that seen in homocystinuric 
patients. 
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Our interest in homocysteine was prompted by the 
possibility that plasma homocysteine may serve as an 
indicator of the status and perhaps the intake of a 
number of vitamins, including folic acid, vitamin B12 , 
and vitamin B6• This possibility derived from the 
large number of studies indicating that methionine 
metabolism is tightly regulated [4-6}, and from 
other studies showing that deficiencies in the above 
vitamins is often associated with hyperho-
mocysteinemia [7-20}. 
Homocysteine is a sulfur amino acid whose me-
tabolism is at the intersection of two metabolic path-
ways: remethylation and transsulfuration (fig. 14-1). 
In remethylation, homocysteine acquires a methyl 
group from N-5-methyltetrahydrofolate (MTHF) or 
from betaine to form methionine. The reaction with 
MTHF occurs in all tissues and is vitamin BI2-depen-
FIGURE 14-1. Homocysteine metabolism: 1, methylene-
tetrahydrofolate reductase; 2, cystathionine-~-synthase; 3, 
cystathionase; THF, tetrahydrofolate; PLP, pyridoxal-5'-
phosphate; and CH3-Bw methylated vitamin B12 • 
dent, while the reaction with betaine is confined 
mainly to the liver and is vitamin BI2-independent. A 
considerable proportion of methionine is then acti-
vated by ATP to form S-adenosylmethionine (SAM). 
SAM serves primarily as a universal methyl donor to 
a variety of acceptors, including guanidinoacetate, 
nucleic acids, neurotransmitters, phospholipids, and 
hormones. S-adenosylhomocysteine (SAH), the by-
product of these methylation reactions, is subse-
quently hydrolyzed, thus regenerating homocysteine, 
which then becomes available to start a new cycle of 
methyl-group transfer. 
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In the transsulfuration pathway, homocysteine 
condenses with serine to form cystathionine in an 
irreversible reaction catalyzed by the pyridoxal-5'-
phosphate (PLP)-containing enzyme, cystathionine 
~-synthase. Cystathionine is hydrolyzed by a second 
PLP-containing enzyme, y-cystathionase, to form cys-
teine and a-ketobutyrate. Excess cysteine is oxidized 
to taurine and inorganic sulfates or excreted in the 
urine. Thus, in addition to the synthesis of cysteine, 
this transsulfuration pathway effectively catabolizes 
excess homocysteine that is not required for methyl 
transfer. It is important to note that since homo-
cysteine is not a normal dietary constituent, the sole 
source of homocysteine is methionine. 
Studies of the regulation of homocysteine metabo-
lism have demonstrated that the utilization of 
homocysteine molecules by the transsulfuration and 
remethylation pathways is nutritionally regulated. 
Mudd and Poole (21J and Mudd et al. (22J have 
shown that when the intake of labile methyl groups 
(i.e., methionine and choline) is modified, the de novo 
synthesis of methionine methyl groups is affected. 
When a basal methionine-containing diet was fed, 
homocysteine moieties were found to cycle through 
the remethylation pathway approximately 1.5 to 
2.0 times before being catabolized through the 
transsulfuration pathway. When dietary methionine 
was halved, the number of cycles per homocysteine 
moiety increased twofold. Conversely, when excess 
dietary methionine was fed, homocysteine cycling 
decreased below basal levels. Similar adaptations to 
changing levels of dietary methionine were observed 
by Eloranta et al. in rats (23]. 
This capacity of the body to discriminate between 
the remethylation and transsulfuration pathways as a 
way to adapt to varying amounts of methionine in the 
diet strongly implies the existence of a coordinate 
regulation between these two pathways. Available 
experimental evidence, obtained primarily from mea-
surements of enzyme activities in vitro, suggests that 
this coordination is achieved by at least two mecha-
nisms. The first mechanism is a function of SAM's 
propensity to act as an allosteric inhibitor of 
methylenetetrahyrofolate reductase (24J and as an 
activator of cystathionine ~-synthase (25]. As such an 
effector, SAM suppresses the synthesis of an impor-
tant substrate (N-5-methyltetrahydrofolate) required 
for remethylation and promotes the initial reaction of 
transsulfuration (cystathionine synthesis). Thus, in-
tracellular SAM concentration is an important deter-
minant of the fate of homocysteine molecules. 
The second mechanism by which remethylation 
and transsulfuration are coordinated consists of the 
regulation of intracellular SAM concentration itself. 
In the liver, SAM synthesis is catalyzed by two en-
zymes that are peculiar to this organ and that, 
although immunologically similar, are different in 
other respects (26-27]. One enzyme, a tetramer of 
high molecular weight, exhibits a high affinity for 
methionine and is thought to function at normal 
physiologic conditions. The second enzyme is a dimer 
of a lower molecular weight, has a low affinity for 
methionine, and is thought to function under condi-
tions of high methionine intake. Thus, changes in 
intracellular methionine, particularly due to dietary 
intake, will affect the rate of SAM synthesis based on 
the activity of the SAM synthetase enzymes. 
The utilization of SAM also is thought to be regu-
lated specifically by a reaction in which the methyl 
group of SAM is transferred to the amino group of 
glycine, forming sarcosine. This reaction is catalyzed 
by glycine N-methyltransferase (GNMT), which is 
abundant in the liver and which is strongly inhibited 
by N-5-methyltetrahydrofolate polyglutamates (29-
30]. Thus, along with intracellular methionine, N-5-
methyltetrahydrofolate participates in the regulation 
of intracellular SAM concentrations. 
When the two mechanisms of regulation are con-
sidered together, the following scenarios can be 
predicted: 
1. When dietary methionine is high, the low 
molecular weight SAM synthetase will rapidly 
convert the incoming methionine to SAM. The 
resulting rise in intracellular SAM concentra-
tion will be associated with: a) inhibition of 
methylenetetrahydrofolate reductase, resulting in 
suppressed N-5-methyltetrahydrofolate synthesis, 
thereby allowing the GNMT enzyme to act near 
full capacity because of suppressed inhibitor (N-5-
methyltetrahydrofolate) concentration, and b) ac-
tivation of the cystathionine ~-synthase enzyme, 
thus increasing the rate of homocysteine catabo-
lism. In this way, homocysteine transsulfuration is 
promoted over remethylation consistent with the 
reduced need for de novo methionine synthesis 
due to the high dietary supply of methionine. 
2. Conversely, when the dietary methionine supply 
is low, SAM concentration would be insufficient 
for inhibiting methylenetetrahydrofolate reduc-
tase, resulting in an elevated rate of N-5-
methyltetrahydrofolate production. The resulting 
rise in intracellular N-5-methyltetrahydrofolate 
concentration will be associated with: a) inhibi-
tion of GNMT and thereby conservation of SAM, 
and b) an increase in the availability of substrate 
for homocysteine remethylation. Thus, remethyla-
tion will be favored over transsulfuration because 
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of a concentration of SAM too low to activate the 
cystathionine ~-synthase enzyme. This is consis-
tent with the increased need for de novo methion-
ine synthesis because of the low dietary input of 
methionine. 
Due to the existence of a cellular homocysteine 
export mechanism, plasma normally contains a small 
amount of homocysteine, averaging 10 J..LmollL 
[31,22}. This export mechanism complements the 
catabolism of homocysteine through transsulfura-
tion; together these mechanisms help maintain low 
intracellular concentrations of this potentially cyto-
toxic sulfur amino acid. In hyperhomocysteinemia, 
plasma homocysteine levels are elevated. Barring 
kidney malfunction, the occurrence of hyperhomocy-
steinemia indicates that homocysteine metabolism 
has in some way been disrupted and that the export 
mechanism is disposing excess homocysteine into 
the blood that has accumulated in the cell. This 
limits intracellular toxicity, but leaves vascular tissue 
exposed to the possibly deleterious effects of excess 
homocysteine. 
The aims of our study were therefore to: (1) to 
determine the relationship between plasma homo-
cysteine concentrations and status and intake of 
folate, vitamin BI2 and vitamin B6; (2) to determine 
the prevalence of hyperhomocysteinemia; (3) to 
determine the contribution of vitamin status and 
intake to the prevalence of hyperhomocysteinemia 
and; (4) to describe the associations between 
plasma homocysteine, vitamin status, and intake 
and prevalence of carotid artery stenosis. This chapter 
IS a summary of our two previous publications 
[33,34}. 
Methods 
SUBJECTS 
Participants were members of the original 
Framingham Heart Study cohort, a population-based 
sample of 5 ,209 men and women originally examined 
in 1948-1952 [35} and followed prospectively to the 
present to assess the occurrence of vascular disease. 
This study was based on 1,401 survivors of the 
original cohort who participated in the 20th biennial 
examination (1989-1990). Homocysteine and carotid 
ultrasound measures were available for 1,041 indi-
viduals (418 men and 623 women) 67-96 years of age 
at the time of data collection. Informed consent was 
obtained from all participants. The protocols for this 
study were approved by the Human Investigations 
Review Committee at New England Medical Center 
and by the Institutional Review Board for Human 
Research at Boston University Medical Center. 
BIOCHEMICAL DETERMINATIONS 
Blood was drawn nonfasting, and plasma total choles-
terol and HDL cholesterol were determined in the 
Framingham Heart Study laboratory using enzymatic 
methods [36,37J. LDL cholesterol was not deter-
mined because the blood samples were taken in a 
nonfasting state. Plasma samples stored frozen at 
-80°C were used for the determination of total 
homocysteine by the method of Araki and Sako [38}, 
plasma folate was determined by a microbial assay 
using a 96-well plate and manganese supplementa-
tion as described by Tamura et al. [39}, vitamin BI2 
using a (Magic) radioassay kit from Ciba-Corning 
(Medfield, MA), and pyridoxal-5f-phosphate by the 
tyrosine decarboxylase method as described by 
Camp et al. [40}. Because of insufficient plasma 
volume, vitamin measures were not available for all 
subjects. 
NUTRIENT INTAKE 
Members of the Framingham cohort received a 
semiquantitative food frequency questionnaire by 
mail [31} when they were scheduled for their 20th 
biennial examination. Subjects returned the com-
pleted questionnaire at the time of their examination. 
Estimated folate and vitamin B6 intakes corresponded 
well to the respective folate and PLP plasma concen-
trations. Vitamin BI2 intake was not, however, corre-
lated with plasma vitamin B12 [31,32}. 
MEASUREMENT OF CAROTID STENOSIS 
At the 20th biennial examination, participants 
underwent a carotid Doppler examination with 
Ultrasonix, high resolution, real-time scanner 
equipped with a 7.5MHz imaging transducer, a 4-
MHz pulse wave Doppler transducer, and a 4-MHz 
continuous wave transducer. For this report, we classi-
fied individuals into two categories based on the maxi-
mum percent diameter stenosis of the more diseased 
artery: 0%-24% stenosis or 25%-100% stenosis. 
STATISTICAL METHODS 
To describe the assocIatIOns between plasma 
homocysteine concentrations and the B vitamins, we 
grouped subjects into deciles of plasma vitamin con-
centration and vitamin intake. We calculated the 
geometric mean plasma homocysteine concentrations 
in each vitamin decile and plotted these values and 
their 95% confidence limits at the median vitamin 
level within each decile. We adjusted mean homo-
cysteine levels for age, sex, and concentration or in-
take of the other B vitamins by analysis of covariance 
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[43J, with all covariates set to their respective sample 
means. We also adjusted all vitamin intakes for en-
ergy [44]. 
To examine the association between the occurrence 
of high plasma homocysteine concentrations and 
these vitamins, we defined high homocysteine as con-
centrations > 14.0 IlmollL (the 90th percentile for 
homocysteine among those subjects whose three 
plasma vitamins levels were above the 70th percen-
tile). We developed a B-vitamin index to describe the 
joint relationships of the three vitamins included in 
these analyses to homocysteine levels. The indices had 
five categories based on percentile values for each 
nutrient. We classified individuals with all three vita-
mins above the 70th percentile into the reference 
category (category 1). Category 2 included individu-
als with all three vitamins above the 50th but at least 
one below the 70th percentile; category 3 included 
those with at least one vitamin above and one vitamin 
below the 50th percentile; category 4 included those 
with all three vitamins below the 50th percentile but 
at least one above the 30th percentile; and category 5 
included individuals with all vitamins below the 30th 
percentile. We determined mean homocysteine con-
centration, the prevalence of high homocysteine, the 
prevalence rate ratio for high homocysteine, and at-
tributable proportion (attributable risk percent [45]) 
within each vitamin index category. We also esti-
mated population attributable proportion, which 
represents the proportion of cases with high homo-
cysteine in the population that can be attributed to 
low plasma vitamin concentrations or vitamin intake. 
To graphically describe the relation of homo-
cysteine to stenosis, we classified men and women 
into quartiles of homocysteine concentration. Within 
each quartile, we computed the prevalence of carotid 
stenosis 2::25% and plotted the prevalence estimates 
at the sex-specific median homocysteine concentra-
tion for that quartile. To adjust for other risk factors 
for carotid stenosis, logistic regression was used 
with stenosis 2::25% as the dependent variable. 
Homocysteine quartiles were modeled using indica-
tor variables to represent the three highest quartiles, 
and relative risk of stenosis for each quartile, com-
pared with the lowest quartile, was estimated as the 
odds ratio derived as the antilogarithm of the logistic 
regression coefficients. To examine the association 
between the nutrition determinants of plasma 
homocysteine and stenosis, we also divided subjects 
into quartiles for each vitamin measure and repre-
sented them in the regression models as indicator 
variables using the highest plasma vitamin quartile as 
the reference category to estimate the relative risk of 
lower nutrient levels. If not otherwise noted, statisti-
cal significance refers to P less than 0.05. 
Results 
HOMOCYSTEINE DISTRIBUTION 
AND PREVALENCE OF HIGH 
HOMOCYSTEINE CONCENTRATIONS 
The mean homocysteine concentration for all subjects 
was 11.91lmollL (median = 11.6IlmollL). Values 
ranged ftom 3.5 to 66.9IlmollL. Homocysteine con-
centration was higher in men than in women and 
increased with age (table 14-1). The increase with age 
remained highly significant (P < 0.001) for men and 
TABLE 14-l. Mean homocysteine and B vitamin status and intake by age and sex 
Plasma concentrations Nutrient intake/4,200KJ 
Homocysteine, Homocysteine, Folate, Vitamin PLP Folate, Vitamin Vitamin 
Sex Age, y n IlmollL & Elevated nmollL B12 pmollL nmollL Ilg B12 llg B6mg 
Men 67-74 239 11.8 25.3 9.3 265 52.6 174 3.7 1.4 
75-79 110 11.9 26.7 9.5 260 49.6 180 3.8 1.3 
80+ 108 14.1 48.3 10.0 255 47.6 204 4.8 1.4 
P (for trend 
by age) <0.001 <0.001 0.41 0.62 0.36 0.02 0.02 0.81 
Women 67-74 310 10.7 19.5 10.4 302 59.9 214 4.0 1.6 
75-79 204 11.9 28.9 10.2 289 52.2 220 4.4 1.5 
80+ 189 13.2 41.4 9.7 290 52.1 199 4.9 1.5 
P (for trend 
by age) <0.001 <0.001 0.60 0.47 0.13 0.23 0.Q3 0.55 
P (sex) 0.003 0.09 0.19 0.001 0.08 <0.001 0.07 0.02 
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women after adjustment for plasma vitamin concen-
trations, but the difference between men and women 
was no longer statistically significant. 
We defined high homocysteine as concentrations 
greater than the 90th percentile among subjects 
with all plasma vitamin levels > 70th percentile 
(14.0IlmollL). Prevalence of high homocysteine was 
29.3% for the entire cohort and over 40% for indi-
viduals SO years of age and older. 
Mean Homocysteine Concentration by 
Vitamin Status and Intake 
FOLATE 
Mean plasma homocysteine concentrations for sub-
jects in the two lowest deciles of plasma folate (below 
4.SnmollL) were 15.6 and 13.7IlmollL. These were 
significantly greater than the mean for subjects in the 
highest decile, which was 11.0 IlmollL (p < 0.01) (fig. 
14-2A). Mean homocysteine concentrations for sub-
jects in the three lowest deciles of folate intake (less 
than 253Ilg/day) were 13.7, 12.9, and 13.2IlmollL, 
respectively, and were significantly greater than the 
mean for subjects in the highest intake decile, which 
was lO.4llmollL (p < 0.01) (fig. 13-3A). 
VITAMIN B12 
Mean homocysteine concentrations were significantly 
elevated for subjects in the lowest decile for vitamin 
B 12 relative to subjects in the highest decile (p < 
0.01). Mean homocysteine concentrations were 15.4 
and 10.91lmollL for subjects in the lowest and high-
est vitamin Bl2 deciles (fig. 14-2B). Subjects in the 
lowest vitamin B12 decile had vitamin Bl2 concentra-
tions below 139pmollL. Vitamin Bl2 intake appeared 
unrelated to mean homocysteine concentration even 
though subjects in the fifth decile had significantly 
higher homocysteine concentrations than subjects in 
the highest decile (p < 0.05) (fig. 13-3B). 
VITAMIN B6 
Mean homocysteine concentrations were significantly 
elevated for subjects in the lowest decile for PLP 
relative to subjects in the highest decile for this vita-
min (p < 0.01). Mean homocysteine concentrations 
were 14.3 and 10.91lmollL for subjects in the lowest 
and highest PLP deciles (fig. 14-2c). Subjects in 
the lowest decile and PLP concentrations below 
lS.l nmollL. For vitamin B6 intake, mean homocy-
steine concentrations were significantly elevated in 
the lowest two deciles (p < 0.01) and the third decile 
(p < 0.05). Mean homocysteine concentrations were 
13.4, 12.4, and 12.31lmollL for subjects in the lowest 
three deciles; the mean in the highest decile was 
10.11lmollL (fig. 14-3c). Subjects in the lowest three 
intake deciles reported consuming less than 1. 7 5 mg/ 
day. 
Homocysteine Concentrations by Overall 
Vitamin Status 
Mean homocysteine and the prevalence of high 
homocysteine increased dramatically across cate-
gories of the B-vitamin index (table 14-2). Mean 
homocysteine concentration was 75% greater in the 
lowest relative to the highest index categories. The 
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FIGURE 14-2. Mean plasma homocysteine concentrations 
(and 95% confidence intervals) by deciles of plasma folate 
(a), vitamin B12 (b) and PLP (c) concentrations. Means 
are adjusted for age, sex and other plasma vitamins. (* sig-
nificantly different from mean in the highest decile {p < 
0.01].) 
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TABLE 14-2. Elevated homocysteine concentrations by B vitamin status 
Mean Prevalence Population 
B vitamin homocysteine Prevalence rate Attributable attributable 
Index I (flmollL) (%) ratio n percent percent 
Highest 89 9.4 10.1 0.0 0.0 
2 128 9.8 12.5 1.2 19.2 1.0 
3 534 11.9* 28.7* 2.8 64.8 33.7 
4 144 14.9* 52.1 * 5.2 80.6 20.6 
Lowest 5 70 16.5* 58.6* 5.8 82.8 11.6 
(total) 66.9 
I Index combines plasma folate, vitamin B12 and PLP concentrations: High (1) = all three B vitamins> 70th percentile; 2 = all vitamins> 50th, at least 1 < 
70th percentile; 3 = vitamins above and below the 50th percentile; 4 = all vitamins < 50th percentile. at least 1 > 30th percentile; low (5) = all three vitamins 
< 30th percentile. 
• Significantly different from category I (P < 0.0l). 
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prevalence of high homocysteine was almost sixfold 
greater among subjects in the lowest index category, 
compared with subjects in the highest category for 
plasma index. Sixty-seven percent of the cases of high 
homocysteine in this cohort of older subjects were 
associated with at least one vitamin concentration 
below the 70th percentile. Although the prevalence 
of high homocysteine was substantially greater in 
lower vitamin categories (4 and 5) than in the middle 
category, this latter category contributed the largest 
share of cases of high homocysteine for the index, 
because it included the largest proportion of the 
cohort. 
Relationship Between Plasma Homocysteine 
and Prevalence of Extracranial Stenosis 
The prevalence of extracranial carotid stenosis ~25% 
was approximately 43% and 34% in men and women, 
respectively. Fig. 14-4 shows the age-adjusted pre-
valence of stenosis across quartiles of plasma 
homocysteine levels. In men, the prevalence of 
stenosis ~25 percent was 27% (95% confidence inter-
val [l7%-38%}) in the lowest homocysteine quartile 
and 58% (95% confidence interval [49%-67%} in 
the highest quartiles (p < 0.001). The correlation in 
women was not as striking as that in men; prevalence 
of stenosis ~25% ranged from 31 % (95% confidence 
interval (24-38%» to 39% (95% confidence interval, 
(31-47%» across homocysteine quartiles (p= 0.03). 
While the risk of stenosis appeared to increase in 
the second homocysteine quartile (9.1-11.3 flmoll 
liter) among men, it did not appear to increase until 
the third homocysteine quartile (1l.4-14.3 flmoll 
liter) among women. Although the prevalence of 
stenosis appeared somewhat greater among men than 
women in the upper quartiles of homocysteine, a test 
of interaction between sex and homocysteine indi-
cated that the trends for prevalence of stenosis ~25% 
were not significantly different for men and women 
(p = 0.07). 
The age- and sex-adjusted odds ratios (OR) for men 
and women combined were significantly increased in 
the third (OR =l.6; 95% confidence interval [l.1-
2.4}) and fourth (OR = 2.1; 95% confidence interval 
[l.5-3.0}) quartiles of homocysteine (~14.4flmoll 
liter) relative to the lowest quartile (:5:9.1 flmolliiter) 
(table 14-3). Adjustment for other risk factors had 
little effect on the ORs. 
The associations between carotid stenosis and the 
plasma vitamins are shown in table 14-4. The preva-
lence of stenosis ~25% was inversely associated with 
both folate (P"end < 0.001) and pyridoxal-5'-phos-
phate (Pmnd = 0.03) after adjustment for age, sex, and 
other risk factors. The OR for stenosis was l.9 (95% 
70 
60 I 50 
\ 
j Stenosis ~ 25% I (%) 40 ~ 30 20 
10 
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Plasma Homocysteine 
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FIGURE 14-4. Age-adjusted prevalence and 95% confi-
dence limits of maximum extracranial carotid artery diam-
eter stenosis ;0:25% by quartile of plasma homocysteine 
concentration in men (squares) and women (circles). 
Homocysteine quartile cutoff values were 9.1, 11.3, and 
14.3I1moliliter. Test for linear trend: P < 0.001 for men, 
P = 0.03 for women. 
TABLE 14-3. Odds ratio of maximal extracranial carotid artery diameter 
stenosis ;0:25% by quartile of plasma homocysteine concentration (n = 1,041) 
Age and sex adjusted Multiple risk factor adjustment! 
Homocysteine 
quartile (I1moliL) Odds ratio 95% CIt P-value Odds Ratio 95% CI P-value 
::;9.1 1.0 1.0 
9.2-11.3 1.1 0.8, 1.6 0.60 1.1 0.8, 1.6 0.58 
11.4-14.3 1.6 1.1, 2.4 0.009 1.6 1.1, 2.3 0.02 
;0:14.4 2.1 1.5, 3.0 <0.001 2.0 1.4, 2.9 <0.001 
Ptrend <0.001 <0.001 
t CI = confidence interval. 
~ Adjusted for sex, age, totallHDL cholesterol ratio, smoking status, and systolic blood pressure. 
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TABLE 14-4. Odds ratios of maximal extracranial carotid artery diameter stenosis ~25% by quartile of plasma vitamins 
Multiple risk factor adjustment 
Multiple risk factor adjustment! plus homocysteine 
Vitamin N Odds ratio 95% CI* P-value Odds ratio 95% CI P-value 
Folate (~g/L) 1,027 
<2.51 1.9 1.3, 2.7 0.001 1.5 1.0, 2.3 0.04 
2.51-4.31 1.4 1.0,2.0 0.08 1.3 0.9, 1.9 0.24 
4.32-7.92 1.2 0.8, 1.8 0.28 1.2 0.8, 1.8 0.35 
~7.93 1.0 1.0 
Prrend <0.001 0.05 
Vitamin B12 (ng/L) 881 
<290 1.4 0.9,2.1 0.11 1.2 0.8, 1.8 0.41 
290-405 1.4 0.9,2.0 0.14 1.2 0.8, 1.8 0.36 
406-572 1.3 0.9,2.0 0.16 1.3 0.9, 1.9 0.24 
~573 1.0 1.0 
P trend 0.11 0.47 
Pyridoxal-5 f -phosphate (nmol/L) 967 
<31.91 1.6 1.1, 2.4 0.02 1.3 0.9,2.0 0.15 
31.91-52.19 1.1 0.7, 1.6 0.67 1.0 0.6, 1.4 0.80 
52.20-89.80 1.2 0.8, 1.7 0.48 1.1 0.7, 1.6 0.71 
~89.81 1.0 1.0 
Ptrend 0.03 0.23 
* CI = confidence interval. 
t Adjusted for sex, age, totallHDL cholesterol ratio, smoking status, and systolic blood pressure. 
~ To convert to SI units, multiply folate values by 2.266 to get values in nmollL and vitamin B12 values by 0.7378 to get values in pmollL. 
confidence interval [l.3-2.7}) in the lowest folate 
quartile and l.6 (95% confidence interval [l.1-2.4}) 
in the lowest pyridoxal-5' -phosphate quartile. Plasma 
vitamin B12 exhibited a weak association with stenosis 
(Pmnd = 0.11). The OR for stenosis was 1.4 (95% 
confidence interval [0.9-2.1} in the lowest vitamin 
B12 quartile compared with the highest quartile. Ad-
justment for homocysteine diminished the strength 
of plasma vitamin associations, but the elevated 
prevalence of stenosis in the lowest plasma folate 
quartile remained evident (OR: l.5; 95% confidence 
interval: l.0-2.3). 
Discussion 
These data suggest an important role for nutntIon 
in homocysteine metabolism. We have demonstrated 
strong, nonlinear, inverse associations between 
homocysteine concentrations and plasma concentra-
tions of folate, vitamin B12 , and vitamin B6 • We ob-
served that individuals with low levels of each of these 
vitamins had high plasma homocysteine concentra-
tions, while those with moderate vitamin levels had 
dramatically lower homocysteine concentrations. 
Homocysteine levels did not differ substantially be-
tween individuals with moderate and high vitamin 
concentrations. 
The results for folate and vitamin B6 intake data are 
consistent with those for the plasma vitamins. Al-
though it is risky to attribute discrete quantitative 
values based on this method of dietary assessment 
[41}, it still may be worth noting that homocysteine 
concentrations were elevated among individuals with 
folate intakes up to 280 flg/day, which is higher than 
the current RDA of 200 and 180 flg/day for adult 
men and women, and vitamin B6 intakes as high as 
l.92 mg/day, which is less than the RDA of 2.0 mgl 
day for men but greater than the RDA of l.6mg/day 
for women. 
Adequate levels of all three vitamins may be 
needed to obtain an optimal homocysteine concentra-
tion. Using the index based on levels of all three 
vitamins, we estimated that approximately two-
thirds of the cases of elevated homocysteine concen-
tration in this cohort were associated with low or 
moderate plasma levels of one or more of the three 
vitamins. 
Our data also provide evidence that plasma 
homocysteine levels are associated with extracranial 
carotid stenosis in a population-based, elderly cohort. 
We observed that risk of stenosis ;::::25 % was increased 
at homocysteine concentrations previously believed to 
be normal, based on levels of homocysteine among 
normative samples. As in our previous analysis, we 
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defined elevated plasma homocysteine as concentra-
tions > 14 ~mol/L (90th percentile among individuals 
with apparently adequate folate, vitamin B12 and 
vitamin B6 status). Stampfer et al. [46} defined 
elevated homocysteine as concentrations greater than 
15.8 ~mol/liter (95th percentile among nondiseased 
control subjects). Joosten et al. [47} defined elevated 
homocysteine as concentrations greater than 
13.9 ~mol/L (mean plus two standard deviations 
among healthy young controls). Genest and cowork-
ers [48} reported 90th and 95th percentile values of 
15.0 and 19.0~mol/L among their normal controls. 
In the present study we observed that risk of stenosis 
was elevated at levels of homocysteine between 11.4 
and 14.3 ~mol/L. These data will require us to recon-
sider the current beliefs regarding standards for 
elevated homocysteine. 
We have also examined the relations between spe-
cific nutrition determinants of hyperhomocysteine-
mia and stenosis in this elderly cohort. We further 
demonstrated that folate and pyridoxal-5' -phosphate 
were linked to stenosis, in large part, due to their 
regulation of plasma homocysteine levels as indicated 
by the diminished odds ratios between stenosis and 
these vitamins after adjustment for homocysteine lev-
els. Although there was some residual association be-
tween plasma folate and stenosis after adjustment for 
homocysteine, the likelihood ratio test statistic would 
suggest that addition of folate to a model containing 
homocysteine did not add any significant contribu-
tion. It is likely that measurement error and biologic 
variability -in both folate and homocysteine might 
explain the residual folate association. 
We demonstrated that the majority of these elderly 
individuals with elevated homocysteine concentra-
tions have insufficient status of folate, vitamin B12, or 
vitamin B6, and that others have demonstrated that 
innocuous vitamin supplementation regimens (in-
cluding folate, B12> and B6) effectively lower moder-
ately elevated plasma homocysteine levels to the 
normal range [l0,20,49-54}. Results of our present 
study provide the rationale for a randomized, con-
trolled trial of the effect of homocysteine-lowering 
vitamin therapy on vascular disease morbidity 
and mortality in hyperhomocysteinemic, elderly 
individuals. 
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